There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
The company, which specializes in the research and development (R&D) of novel, cannabinoid-based drug therapies, has announced the filing of a provisional patent application for its proprietary biosynthesis process for the manufacture of cannabinoids that are identical to those found in nature http://theseedinvestor.com/cannabis-news/is-inmed-building-a-billion-dollar-cannabis-business-without-touching-the-plant.
This technology allows them to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.
InMed’s cannabinoid biosynthesis program is one of three core assets, which also include the bioinformatics assessment tool to target specific cannabinoids against important diseases, as well as the drug development program, which includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.
Here is a short video that provides an overview.
If you've been watching all of the announcements on InMed lately, we think you should definitely take a look.
